MHC class I epitope delivering polypeptides
US-12037367-B2 · Jul 16, 2024 · US
Cytomegalovirus
Cytomegalovirus · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K16/089 |
| Official title | {Cytomegalovirus} |
| Display label | Cytomegalovirus |
| Total patents | 91 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 7 |
| 2016 | 10 |
| 2017 | 2 |
| 2018 | 9 |
| 2019 | 5 |
| 2020 | 9 |
| 2021 | 10 |
| 2022 | 12 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 3 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Targeting cell tropism receptors to inhibit cytomegalovirus infection
US-11484570-B2 · Nov 1, 2022 · US
Identification and Elimination of HCMV-Infected Cells
US-2022324947-A1 · Oct 13, 2022 · US
Passive antibody dependent cell-mediated activation
US-11459378-B2 · Oct 4, 2022 · US
Mhc class i epitope delivering polypeptides
US-2022306701-A1 · Sep 29, 2022 · US
Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
US-2022288191-A1 · Sep 15, 2022 · US
De-immunized shiga toxin a subunit effector polypeptides for applications in mammals
US-2022275030-A1 · Sep 1, 2022 · US
CMV neutralizing antigen binding proteins
US-11230591-B2 · Jan 25, 2022 · US
Broadly neutralizing anti-human cytomegalovirus (HCMV) antibodies and methods of use thereof
US-11185582-B2 · Nov 30, 2021 · US
Antibodies and peptides to treat HCMV related diseases
US-11174322-B2 · Nov 16, 2021 · US
Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
US-2021338800-A1 · Nov 4, 2021 · US
HUMAN iPSC-DERIVED BRAIN ORGANOIDS AND USES THEREOF
US-2021300998-A1 · Sep 30, 2021 · US
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US-11129891-B2 · Sep 28, 2021 · US
Mhc class i epitope delivering polypeptides
US-2021253648-A1 · Aug 19, 2021 · US
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US-11051497-B2 · Jul 6, 2021 · US
Systems and methods to produce b cells genetically modified to express selected antibodies
US-2021198344-A1 · Jul 1, 2021 · US
Methods and compositions comprising purified recombinant polypeptides
US-2021115126-A1 · Apr 22, 2021 · US
Cell-targeting molecules comprising protease-cleavage resistant, shiga toxin a subunit effector polypeptides and carboxy-terminal moieties
US-2021017512-A1 · Jan 21, 2021 · US
Targeting Cell Tropism Receptors to Inhibit Cytomegalovirus Infection
US-2020376077-A1 · Dec 3, 2020 · US
Methods and compositions comprising purified recombinant polypeptides
US-10822404-B2 · Nov 3, 2020 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K16/089?
- CPC C07K16/089 is the Cooperative Patent Classification code for “Cytomegalovirus.”
- How many patents are filed under CPC C07K16/089 (Cytomegalovirus)?
- Our database includes 91 publications tagged with this CPC code.
- Is patent activity under CPC C07K16/089 growing?
- Publication counts under this code: 7 in 2024 vs 8 in 2025 (latest complete years).